1. What You Didn't Know About AF and Renal Dysfunction

3. Percentage of Strokes Attributable to AF Increases With Age

4. Changes in Kidney Function Over Time

6. Antithrombotic Therapy in Patients With AF and CKD

8. Key Pharmacokinetics of NOACs Absorption, Distribution, Metabolism, Excretiona-d

9. Drug-Drug Interactions With NOACs

12. NOAC Dosing Considerations for Nonvalvular AF With Renal Adjustments*

13. Efficacy of Apixaban in Relation to Renal Function in Patient With AF

14. Subgroup Analysis in ENGAGE AF - TIMI 48 Stroke/SEE by Baseline CrCL*

15. Ischemic Stroke by CrCl Decile in ENGAGE AF – TIMI 48

16. Effect of CrCl on Risk for Ischemic Stroke/SEE in ENGAGE AF – TIMI 48 Edoxaban 60 mg vs Warfarin

17. NOAC Dose Comparisons

18. EU Label Simulated Dabigatran Treatment

19. Renal Dysfunction Efficacy and Safety of Apixabana and Dabigatranb With Continuous Analysis of Renal Function

20. Abbreviations

21. Abbreviations (cont)

22. References

23. References (cont)

24. References (cont)

25. References (cont)